Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 3 N=653 Prescription Opioid Addiction Treatment Study (POATS)
Opiate Dependence · Substance-related Disorders · Opioid-related Disorders
Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
Phase 4 N=54 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Opiate Addiction
Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
N/A N=87 Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
HIV Prevention · Opioid-Related Disorders
Primary: Treatment Engagement — 23; 11; 6 participants — p=<0.001
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
Phase 2 N=25 Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Opiate Substitution Treatment · Opioid-Related Disorders
Primary: Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) — -5.00; -13.34 score on a scale
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
Phase 2 N=15 Testosterone Replacement for Male Opioid Agonist Maintained Patients
Chronic Pain · Opioid Addiction · Symptomatic Hypogonadism
Primary: Number of Participants Demonstrating Abstinence — 5; 4 Participants
Phase 2 N=30 Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants
N/A N=76 Evaluation of a Computerized Opioid Overdose Prevention Program
Computer + Fluency · Computer Only · Treatment as Usual
Primary: Knowledge Gain — 30.6; 30.5; 27.56; 40.7 units on a scale
Phase 3 N=49 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants
N/A N=329 Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
Opiate Addiction
Primary: Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program) — 4.99; 5.67; 3.71 Mean Number of Outpatient…
N/A N=49 Consensus-based Algorithms to Address Opioid Misuse Behaviors Among Individuals Prescribed Long-term Opioid Therapy
Opioid Misuse · Chronic Pain
Primary: Feasibility of Algorithms — 7; 13 Participants
N/A N=155 Technology for MAT in Primary Care - Phase 2
Opioid-use Disorder
Primary: Urine Drug Screening Test Results — 92.3; 92.0; 1.9; 2.0 percentage of participants positive
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
Phase 3 N=117 Improving Treatment Outcomes for Prescription Opioid Dependence
Drug Dependence
Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77
N/A N=335 Evaluating the Impact of the Bridge Clinic in Patients With Opioid Use Disorder
Opioid Use · Opioid-use Disorder
Primary: Hospital Length of Stay — 232.1; 215.0 Hours
N/A N=45 We The Village Family Support Study
Community Reinforcement And Family Training · Family Health · Substance-Related Disorders
Primary: Treatment Entry: IP Treatment Status — 10; 8; 6 count of participants — p=0.02578184
N/A N=102 Optimizing Pregnancy and Treatment Interventions for Moms 2.0
Pregnancy, High Risk · Opioid-Related Disorders · Pregnancy Related
Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days
N/A N=19 mHealth for Patient Self-Management of Opioid Use Disorder
Opioid-use Disorder
Primary: Usability Score — 89.5 score on a scale
Phase 3 N=21 Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Opioid Addiction
Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores